guest ::
| Home > Publications database > Top 10 research priorities in colorectal cancer: results from the Colorectal Cancer Priority-Setting Partnership. > print |
| Home > Publications database > Top 10 research priorities in colorectal cancer: results from the Colorectal Cancer Priority-Setting Partnership. > print |
| 001 | 179959 | ||
| 005 | 20240918105259.0 | ||
| 024 | 7 | _ | |a 10.1007/s00432-022-04042-w |2 doi |
| 024 | 7 | _ | |a pmid:35579718 |2 pmid |
| 024 | 7 | _ | |a 0084-5353 |2 ISSN |
| 024 | 7 | _ | |a 0171-5216 |2 ISSN |
| 024 | 7 | _ | |a 0943-9382 |2 ISSN |
| 024 | 7 | _ | |a 1432-1335 |2 ISSN |
| 024 | 7 | _ | |a altmetric:128446823 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-01008 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Klotz, Rosa |b 0 |
| 245 | _ | _ | |a Top 10 research priorities in colorectal cancer: results from the Colorectal Cancer Priority-Setting Partnership. |
| 260 | _ | _ | |a Berlin |c 2023 |b Springer |
| 264 | _ | 1 | |3 online |2 Crossref |b Springer Science and Business Media LLC |c 2022-05-17 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1726649554_11602 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2023 Apr;149(4):1561-1568 |
| 520 | _ | _ | |a Colorectal cancer (CRC) is the third most frequent cause of cancer death in the word. Which aspects of research into CRC should be accorded the highest priority remains unclear, because relevant stakeholders, such as patients, nurses, and physicians, played hardly any part in the development of research projects. The goal in forming the CRC Priority-Setting Partnership (PSP) was to bring all relevant stakeholders together to identify and prioritize unresolved research questions regarding the diagnosis, treatment, and follow-up of CRC.The CRC PSP worked in cooperation with the British James Lind Alliance. An initial nationwide survey was conducted, and evidence uncertainties were collected, categorized, summarized, and compared with available evidence from the literature. The as-yet unresolved questions were (provisionally) ranked in a second national wide survey, and at a concluding consensus workshop all stakeholders came together to finalize the rankings in a nominal group process and compile a top 10 list.In the first survey (34% patients, 51% healthcare professionals, 15% unknown), 1102 submissions were made. After exclusion of duplicates and previously resolved questions, 66 topics were then ranked in the second survey (56% patients, 39% healthcare professionals, 5% unknown). This interim ranking process revealed distinct differences between relatives and healthcare professionals. The final top 10 list compiled at the consensus workshop covers a wide area of research topics.All relevant stakeholders in the CRC PSP worked together to identify and prioritize the top 10 evidence uncertainties. The results give researchers and funding bodies the opportunity to address the most patient-relevant research projects. It is the first detailed description of a PSP in Germany, and the first PSP on CRC care worldwide. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 542 | _ | _ | |i 2022-05-17 |2 Crossref |u https://creativecommons.org/licenses/by/4.0 |
| 542 | _ | _ | |i 2022-05-17 |2 Crossref |u https://creativecommons.org/licenses/by/4.0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Colorectal neoplasms |2 Other |
| 650 | _ | 7 | |a Forschungspartnerschaft |2 Other |
| 650 | _ | 7 | |a Patient participation |2 Other |
| 650 | _ | 7 | |a Priority-Setting Partnership |2 Other |
| 700 | 1 | _ | |a Holze, Magdalena |b 1 |
| 700 | 1 | _ | |a Dörr-Harim, Colette |b 2 |
| 700 | 1 | _ | |a Grohmann, Erich |b 3 |
| 700 | 1 | _ | |a Nied, Barbara |b 4 |
| 700 | 1 | _ | |a Lebert, Burkhard |b 5 |
| 700 | 1 | _ | |a Weg-Remers, Susanne |0 P:(DE-He78)76dcc66f81ef265e1968a39c42318846 |b 6 |u dkfz |
| 700 | 1 | _ | |a Lutz, Claudia |b 7 |
| 700 | 1 | _ | |a Meißler, Karin |b 8 |
| 700 | 1 | _ | |a Schloss, Patrick |b 9 |
| 700 | 1 | _ | |a Ullrich, Charlotte |b 10 |
| 700 | 1 | _ | |a Frankenhauser, Susanne |b 11 |
| 700 | 1 | _ | |a Lutter, Heidi |b 12 |
| 700 | 1 | _ | |a Bühler, Diedrich |b 13 |
| 700 | 1 | _ | |a Ahmed, Azaz |b 14 |
| 700 | 1 | _ | |a Gronlund, Toto |b 15 |
| 700 | 1 | _ | |a Mihaljevic, André L |0 0000-0003-1902-657X |b 16 |
| 700 | 1 | _ | |a Darmkrebs, Forschungspartnerschaft |b 17 |e Collaboration Author |
| 700 | 1 | _ | |a Cancer, Steering Group Forschungspartnerschaft Darmkrebs/Priority Setting Colorectal |b 18 |e Collaboration Author |
| 700 | 1 | _ | |a Mihaljevic, André |b 19 |
| 700 | 1 | _ | |a Klotz, Rosa |b 20 |
| 700 | 1 | _ | |a Dörr-Harim, Colette |b 21 |
| 700 | 1 | _ | |a Bühler, Diedrich |b 22 |
| 700 | 1 | _ | |a Dörr-Harim, Colette |b 23 |
| 700 | 1 | _ | |a Frankenhauser, Susanne |b 24 |
| 700 | 1 | _ | |a Gapp-Frasch, Sylvia |b 25 |
| 700 | 1 | _ | |a Grohmann, Erich |b 26 |
| 700 | 1 | _ | |a Helmstädter, Volker |b 27 |
| 700 | 1 | _ | |a Hey, Christa |b 28 |
| 700 | 1 | _ | |a Hey, Werner |b 29 |
| 700 | 1 | _ | |a Klotz, Rosa |b 30 |
| 700 | 1 | _ | |a Mihaljevic, André |b 31 |
| 700 | 1 | _ | |a Lebert, Burkhard |b 32 |
| 700 | 1 | _ | |a Lutz, Claudia |b 33 |
| 700 | 1 | _ | |a Lutter, Heidi |b 34 |
| 700 | 1 | _ | |a Lutz, Claudia |b 35 |
| 700 | 1 | _ | |a Meißler, Karin |b 36 |
| 700 | 1 | _ | |a Nied, Barbara |b 37 |
| 700 | 1 | _ | |a Schloss, Patrick |b 38 |
| 700 | 1 | _ | |a Stegmüller, Susanne |b 39 |
| 700 | 1 | _ | |a Stünzi, Peter |b 40 |
| 700 | 1 | _ | |a Trabold-Hauk, Angelika |b 41 |
| 700 | 1 | _ | |a Ullrich, Charlotte |b 42 |
| 700 | 1 | _ | |a Weg-Remers, Susanne |0 P:(DE-He78)76dcc66f81ef265e1968a39c42318846 |b 43 |u dkfz |
| 700 | 1 | _ | |a Wensing, Michel |b 44 |
| 773 | 1 | 8 | |a 10.1007/s00432-022-04042-w |b Springer Science and Business Media LLC |d 2022-05-17 |3 journal-article |2 Crossref |t Journal of Cancer Research and Clinical Oncology |y 2022 |x 0171-5216 |
| 773 | _ | _ | |a 10.1007/s00432-022-04042-w |0 PERI:(DE-600)1459285-X |n 4 |p 1561-1568 |t Journal of cancer research and clinical oncology |v 149 |y 2023 |x 0171-5216 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:179959 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)76dcc66f81ef265e1968a39c42318846 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 43 |6 P:(DE-He78)76dcc66f81ef265e1968a39c42318846 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J CANCER RES CLIN : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-21 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-21 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-10-21 |
| 920 | 1 | _ | |0 I:(DE-He78)M100-20160331 |k M100 |l M100 Krebsinformationsdienst |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)M100-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| 999 | C | 5 | |2 Crossref |u BMBF Partizipation in der Forschung: Patienten aktiv beteiligen - DLR Gesundheitsforschung. In: Dtsch. Zent. Für Luft Raumfahrt EV - DLR Gesundheitsforschung. https://www.gesundheitsforschung-bmbf.de/de/partizipation-in-der-forschung-patienten-aktiv-beteiligen-12816.php |
| 999 | C | 5 | |2 Crossref |u British Medical Journal (2021) Patient and public partnership. In: BMJ Author Hub. https://authors.bmj.com/policies/patient-public-partnership/ |
| 999 | C | 5 | |a 10.1016/S0140-6736(13)62229-1 |9 -- missing cx lookup -- |1 I Chalmers |p 156 - |2 Crossref |u Chalmers I, Bracken MB, Djulbegovic B et al (2014) How to increase value and reduce waste when research priorities are set. Lancet 383:156–165. https://doi.org/10.1016/S0140-6736(13)62229-1 |t Lancet |v 383 |y 2014 |
| 999 | C | 5 | |a 10.1136/bmj.i6627 |1 S Crowe |9 -- missing cx lookup -- |2 Crossref |u Crowe S, Giles C (2016) Making patient relevant clinical research a reality. BMJ 355:i6627. https://doi.org/10.1136/bmj.i6627 |t BMJ |v 355 |y 2016 |
| 999 | C | 5 | |a 10.1007/978-1-4419-1348-7 |1 M Feuerstein |y 2011 |2 Crossref |u Feuerstein M, Ganz PA (2011) Health services for cancer survivors: practice, policy and research, 2011th edn. Springer, New York |9 -- missing cx lookup -- |
| 999 | C | 5 | |2 Crossref |u James Lind Alliance (2021a) The JLA Guidebook. v.10. https://www.jla.nihr.ac.uk/jla-guidebook/. Accessed 25 Aug 2021 |
| 999 | C | 5 | |2 Crossref |u James Lind Alliance (2021b) The PSPs. https://www.jla.nihr.ac.uk/priority-setting-partnerships/. Accessed 11 Dec 2021 |
| 999 | C | 5 | |9 -- missing cx lookup -- |a 10.26092/elib/229 |2 Crossref |u Jilani H, Rathjen KI, Schilling I, Herbon C, Scharpenberg M, Brannath W, Gerhardus A (2020) Handreichung zur Patient*innenbeteiligung an klinischer Forschung, Version 1.0, Universität Bremen. https://doi.org/10.26092/elib/229 |
| 999 | C | 5 | |a 10.1016/S1470-2045(20)30179-0 |9 -- missing cx lookup -- |1 R Klotz |p e295 - |2 Crossref |u Klotz R, Doerr-Harim C, Ahmed A et al (2020) Top ten research priorities for pancreatic cancer therapy. Lancet Oncol 21:e295–e296. https://doi.org/10.1016/S1470-2045(20)30179-0 |t Lancet Oncol |v 21 |y 2020 |
| 999 | C | 5 | |a 10.1111/j.1464-410X.2011.10609.x |9 -- missing cx lookup -- |1 A Lophatananon |p 1040 - |2 Crossref |u Lophatananon A, Tyndale-Biscoe S, Malcolm E et al (2011) The James Lind Alliance approach to priority setting for prostate cancer research: an integrative methodology based on patient and clinician participation. BJU Int 108:1040–1043. https://doi.org/10.1111/j.1464-410X.2011.10609.x |t BJU Int |v 108 |y 2011 |
| 999 | C | 5 | |2 Crossref |u Mihaljevic AL (2022) Forschungspartnerschaft Darmkrebs. https://www.forschungspartnerschaft.de/partnerschaften/darmkrebs/ |
| 999 | C | 5 | |2 Crossref |u Motel-Klingebiel A, Wurm S, Tesch-Römer C (2010) Altern im Wandel: Befunde des Deutschen Alterssurveys. Kohlhammer Verlag |
| 999 | C | 5 | |2 Crossref |u NIHR (2021) Briefing notes for researchers - public involvement in NHS, health and social care research. https://www.nihr.ac.uk/documents/briefing-notes-for-researchers-public-involvement-in-nhs-health-and-social-care-research/27371#Co-production |
| 999 | C | 5 | |a 10.1111/tbj.13525 |9 -- missing cx lookup -- |1 NA Nixon |p 488 - |2 Crossref |u Nixon NA, Simmons C, Lemieux J, Verma S (2020) Research priorities in metastatic breast cancer: a James Lind Alliance Priority Setting Partnership. Breast J 26:488–493. https://doi.org/10.1111/tbj.13525 |t Breast J |v 26 |y 2020 |
| 999 | C | 5 | |2 Crossref |u Oxford Centre for Evidence-Based Medicine (2009) Levels of Evidence. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence |
| 999 | C | 5 | |a 10.1016/S0140-6736(04)17494-1 |9 -- missing cx lookup -- |1 N Partridge |p 1923 - |2 Crossref |u Partridge N, Scadding J (2004) The James Lind Alliance: patients and clinicians should jointly identify their priorities for clinical trials. Lancet Lond Engl 364:1923–1924. https://doi.org/10.1016/S0140-6736(04)17494-1 |t Lancet Lond Engl |v 364 |y 2004 |
| 999 | C | 5 | |a 10.1007/978-3-662-48712-9_1 |9 -- missing cx lookup -- |1 R Pritzkuleit |p 3 - |2 Crossref |u Pritzkuleit R, Katalinic A (2016) Demografische Entwicklung und Krebsentwicklung in Deutschland. In: Keck Tobias, Hopt Ulrich T (eds) Onkologische Chirurgie bei alten Patienten, 1st edn. Springer Verlag, Heidelberg Berlin, pp 3–11 |y 2016 |
| 999 | C | 5 | |a 10.1136/bmj.f2614 |1 T Richards |9 -- missing cx lookup -- |2 Crossref |u Richards T, Montori VM, Godlee F et al (2013) Let the patient revolution begin. BMJ 346:f2614. https://doi.org/10.1136/bmj.f2614 |t BMJ |v 346 |y 2013 |
| 999 | C | 5 | |2 Crossref |u Robert-Koch Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (2015) Krebs in Deutschland 2011/2012. E |
| 999 | C | 5 | |2 Crossref |u Statistisches Bundesamt (2009) Bevölkerung Deutschlands bis 2060. 12. koordinierte Bevölkerungsvorausberechnung. Wiesbaden |
| 999 | C | 5 | |1 R Suzman |y 2011 |2 Crossref |u Suzman R, Beard J (2011) Global health and aging. World Health Organization |t Global health and aging |
| 999 | C | 5 | |2 Crossref |u Zentrum für Krebsregisterdaten, GEKID (2021) Krebs in Deutschland für 2017/2018 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|